Point-of-care testing (POCT) is essential for the rapid detection facilitating better disease diagnosis, monitoring, and management. It is highly specialized for quick medical decisions, as the diseases can be diagnosed at early stage, resulting for improving health outcomes for patients by enabling the early start of treatment.
HOFFMANN-LA ROCHE LTD. and Abbott Laboratories. – Notable Participants in Asia Pacific Point-of-Care Diagnostic Market
A few of the most notable companies occupying a considerable share of the market are F. HOFFMANN-LA ROCHE LTD., Danaher Corporation, BIO-RAD LABORATORIES INC., Abbott Laboratories, Siemens AG, Becton, Dickinson, and Company (BD), Nova Biomedical Corporation, Talis Biomedical Corporation, Quidel Corporation, and Chembio Diagnostics, Inc.
Market leaders are involved in partnerships, product launches, acquisitions, and other strategies to improve their performance and consolidate the market position. For instance, Mylab will now establish PoC testing systems at doctor clinics, nursing homes, community health centers, airports, etc. Such platforms will offer significant opportunities for the market. Additionally, in November 2018, SELECTBIO organized the Asia Diagnostics Summit in Taiwan, focusing on point of care diagnostics, rapid and low-cost diagnostics for deployment worldwide, liquid biopsies for cancer, and the development of immunoassays for various analyte classes of relevance in diagnostics.
Prominent players in the Asia Pacific Point-of-Care Diagnostic market are focusing on organic strategies such as product launches, product approvals, and geographic and manufacturing expansions. These strategies help them strengthen their market positions, along with allowing them to broaden their geographic footprints. Additionally, various companies are undertaking acquisitions to garner their significance and remain competitive in the market. A few of the vital developments in the Asia Pacific Point-of-Care Diagnostic market are mentioned below:
| Year | News | Region |
| 2020 | Vela Diagnostics received CE approval ViroKey Flu A/B & RSV RT-PCR extension kit for the application of in vitro diagnostics. | Singapore |
